Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
CYTOKINETICS INC (CYTK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "CYTOKINETICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Completed Enrollment in SEQUOIA-HCM, Pivotal Phase 3 Trial of Aficamten in Obstructive HCM; On Track for Topline Results by the End of the Year Initiated Enrollment in MAPLE-HCM, a Phase 3 Clinical Trial Comparing Aficamten and Metoprolol in Obstructive HCM ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Non-Obstructive HCM, Expected to Start in September 2023 Company Reduces Projected Spending by Approximately 15% and Revises 2023 Financial Spending Guidance SOUTH SAN FRANCISCO, Calif., Aug. 3, 2023 -"
03/01/2023 8-K Quarterly results
Docs: "CYTOKINETICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS Company Received Complete Response Letter from FDA for New Drug Application for Omecamtiv Mecarbil Data from Cohort 4 of REDWOOD-HCM to be Presented at the American College of Cardiology Scientific Sessions; Results Expected from SEQUOIA-HCM in Q4 2023 Second Interim Analysis of COURAGE-ALS Expected to Occur in Q2 2023 Company Provides 2023 Financial Guidance; More than 2 Years of Cash Runway SOUTH SAN FRANCISCO, Calif., Mar. 1, 2023 -"
08/04/2022 8-K Quarterly results
Docs: "CYTOKINETICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil Scheduled for December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 Company Revises 2022 Financial Guidance; Reduces Projected Spending for 2022 SOUTH SAN FRANCISCO, Calif., Aug. 4, 2022 -"
05/04/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
11/03/2021 8-K Quarterly results
Docs: "Cytokinetics Reports Third Quarter 2021 Financial Results"
08/05/2021 8-K Quarterly results
Docs: "Cytokinetics Reports Second Quarter 2021 Financial Results"
05/06/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/04/2020 8-K Quarterly results
Docs: "Cytokinetics Reports Third Quarter 2020 Financial Results"
08/06/2020 8-K Quarterly results
10/31/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
Docs: "Cytokinetics Reports Second Quarter 2019 Financial Results"
05/09/2019 8-K Quarterly results
Docs: "Cytokinetics Reports First Quarter 2019 Financial Results"
02/21/2019 8-K Quarterly results
11/01/2018 8-K Quarterly results
Docs: "Cytokinetics, Inc. Reports Third Quarter 2018 Financial Results"
07/26/2018 8-K Quarterly results
Docs: "Cytokinetics, Inc. Reports Second Quarter 2018 Financial Results"
04/26/2018 8-K Quarterly results
Docs: "Cytokinetics, Inc. Reports First Quarter 2018 Financial Results"
02/15/2018 8-K Quarterly results
Docs: "Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results"
10/26/2017 8-K Quarterly results
Docs: "Cytokinetics, Incorporated Condensed Consolidated Statements of Operations Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2017 2016 2017 2016"
08/02/2017 8-K Quarterly results
04/27/2017 8-K Form 8-K - Current report
02/16/2017 8-K Form 8-K - Current report
10/27/2016 8-K Form 8-K - Current report
07/28/2016 8-K Quarterly results
Docs: "Cytokinetics, Incorporated Condensed Consolidated Statements of Operations Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, 2016 2015 2016 2015 Revenues: Research and development revenues from related parties $ 3,515 $ 3,510 $ 7,811 $ 6,301 Research and development, grant and other revenues 337 — 488 — License revenues from related parties 1,950 3,032 5,923 4,655 Total revenues 5,802 6,542 14,222 10,956 Operating Expenses: Research and development 9,723 12,636 23,256 21,592 General and administrative 7,090 4,495 13,931 8,862 Total operating expenses 16,813 17,131 37,187 30,454 Operating loss Interest and other income, net 38 75 Net loss $ $ $ $ Net loss per share - basic and diluted $ $ $ $ Weighted average shares used in computing net loss per share - basic and d..."
04/28/2016 8-K Quarterly results
Docs: "Cytokinetics, Incorporated Condensed Consolidated Statements of Operations Three Months Ended March 31, March 31, 2016 2015 Revenues: Research and development revenues from related parties $ 4,296 $ 2,791 Research and development, grant and other revenues 151 — License revenues from related parties 3,974 1,623 License revenues — — Total revenues 8,421 4,414 Operating Expenses: Research and development 13,534 8,956 General and administrative 6,841 4,367 Total operating expenses 20,375 13,323 Operating loss Interest and other income , net 37 Net loss $ $ Net loss per share - basic and diluted $ $ Weighted average shares used in computing net loss per share - basic and diluted 39,592 38,675 Cytokinetics, Incorporated Condensed Consolidated Balance Sheets March 31, December 31, 2016 2015 As..."
02/16/2016 8-K Quarterly results
Docs: "Cytokinetics, Incorporated Condensed Consolidated Statements of Operations Three Months Ended Year Ended December 31, December 31, December 31, December 31, 2015 2014 2015 2014 Revenues: Research and development revenues from related parties $ 4,578 $ 16,110 $ 14,665 $ 19,538 Research and development, grant and other revenues 48 3,377 75 17,566 License revenues from related parties 5,131 — 13,918 — License revenues — 2,271 — 9,836 Total revenues 9,757 21,758 28,658 46,940 Operating Expenses: Research and development 13,249 8,779 46,398 44,426 General and administrative 5,529 4,558 19,667 17,268 Total operating expenses 18,778 13,337 66,065 61,694 Operating income 8,421 Interest and other income , net 22 108 Net income $ $ 8,443 $ $ Net income per share - basic and $ $ 0.23 $ $ Weighted ..."
10/29/2015 8-K Quarterly results
Docs: "Cytokinetics, Incorporated Condensed Consolidated Statements of Operations Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2015 2014 2015 2014 Revenues: Research and development revenues from related parties $ 3,786 $ 1,920 $ 10,087 $ 3,428 Research and development, grant and other revenues 27 4,761 27 14,189 License revenues from related parties 4,132 — 8,787 — License revenues — 2,734 — 7,565 Total revenues 7,945 9,415 18,901 25,182 Operating Expenses: Research and development 11,557 11,420 33,149 35,647 General and administrative 5,276 3,993 14,138 12,710 Total operating expenses 16,833 15,413 47,287 48,357 Operating loss Interest and other, net 39 27 114 86 Net loss $ $ $ $ Net loss per share - basic and diluted $ $ $ $ Weighted average s..."
07/29/2015 8-K Quarterly results
Docs: "CYTOKINETICS, INC. REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS"
04/30/2015 8-K Quarterly results
Docs: "CYTOKINETICS, INCORPORATED REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS"
02/12/2015 8-K Quarterly results
Docs: "CYTOKINETICS, INCORPORATED REPORTS FOURTH QUARTER 2014 FINANCIAL RESULTS"
10/30/2014 8-K Quarterly results
Docs: "CYTOKINETICS, INCORPORATED REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS"
07/30/2014 8-K Quarterly results
Docs: "CYTOKINETICS, INCORPORATED REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS"
05/06/2014 8-K Quarterly results
Docs: "CYTOKINETICS, INCORPORATED REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy